厄洛替尼治疗老年晚期非小细胞肺癌的临床效果

Clinical Effect of Erlotinib in Treatment of Advanced Non-small Cell Lung Cancer in Elderly

目的探讨老年晚期非小细胞肺癌患者应用厄洛替尼的治疗效果。方法选取2015年1月-2017年12月在大连市第三人民医院治疗的54例老年晚期非小细胞肺癌患者，给予厄洛替尼150mg口服，1次／d，持续用药直至肿瘤进展或出现不可耐受的不良反应。结果54例可评价的患者中位生存期11．1个月；无疾病进展时间6．2个月。出现皮疹的患者与无皮疹出现的患者无疾病进展时间差异有统计学意义（P〈0．05）。客观缓解率51．85％、疾病控制率68．52％。疾病控制率：男性低于女性、未出现皮疹患者低于出现皮疹患者、非腺癌患者低于腺癌患者、吸烟患者低于不吸烟患者，差异均有统计学意义（P〈0．05）。影响客观缓解率与疾病控制率的多因素分析结果提示，病理类型是影响疾病控制率的独立因素。最常见的不良反应为皮疹和腹泻，大部分为Ⅰ～Ⅱ度。结论老年晚期非小细胞肺癌患者接受厄洛替尼治疗的效果较好，不良反应较轻，耐受性较好，值得推广使用。

Objective To investigate the efficacy of erlotinib in the treatment of advanced non-small cell lung cancer in elderly patients. Methods A total of 54 elderly patients with advanced non-small cell lung cancer, which were collected in the Third People＇s Hospital of Dalian City from January 2015 to December 2017, were given erlotinib 150 mg orally, once a day, until tumor progression or intolerable adverse reactions occurrence. Results The median survival time of 54 evaluable patients was 11.1 months, and the progression free survival time was 6.2 months. There was a significant difference in progression free survival time between patients with rash and those without rash （P〈0.05）. The objective remission rate was 51.85% and the disease control rate was 68.52%. The disease control rate in male, patients without rash, patients without pancreatic cancer, and smoking patients were significantly lower than female, patients with rash, patients with pancreatic cancer and non-smoking patients, respectively （P〈0.05）. The multivariate analysis on objective remission rate and disease control rate suggested that pathological type was an independent factor affecting disease control rate. The most common adverse reactions were rash and diarrhea, most of which were grade to. Conclusion The effect of erlotinib in the treatment of elderly patients with advanced nonsmall cell lung cancer is better, less adverse reactions, better tolerance, which is worthy of application.